Table 1.
FORTA classes for items belonging to the indications with the highest and lowest overall mean consensus coefficienta
| EURO- FORTA class (2018) | FORTA class/consensus coefficient | Mean consensus coefficient | EURO-FORTA class 2022(original FORTA class shown in parentheses if different from the consensus results) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| The Netherlands [n = 4] | Italy [n = 5] | Nordic countries [n = 4] | Spain [n = 4] | Poland [n = 7] | UK/Ireland [n = 4] | Germany/Austria/Switzerland [n = 20] | ||||
| Highest overall mean consensus coefficient (acute coronary syndrome = 0.981) | ||||||||||
| Substance/group | ||||||||||
| Renin-angiotensin-system blocker: ACE inhibitors | A |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
1.000 | A |
| Acetylsalicylic acid | A |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
1.000 | A |
| Unfractionated heparin and low molecular weight heparin | A |
A 0.750 |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
0.964 | A |
| Frequency-lowering β-blockers, e.g. metoprolol or bisoprolol | A |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
1.000 | A |
| Atorvastatin | A |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
1.000 | A |
| Nitroglycerin spray, single use, acute as on-demand medication | A |
A 1.000 |
A 1.000 |
A 1.000 |
A 1.000 |
A 0.929 |
A 1.000 |
A 0.947 |
0.982 | A |
| Clopidogrel, prasugrel |
B A for stent |
B 0.875 A for stent 1.000 |
B 1.000 A for stent 1.000 |
B 1.000 A for stent 1.000 |
B 1.000 A for stent 1.000 |
B 1.000 A for stent 0.857 |
A 1.000 A for stent 1.000 |
A 1.000 A for stent 1.000 |
0.982 0.976 |
B A for stent |
| Thrombolytics, especially rTPA | B |
C 1.000 |
B 0.833 |
B 1.000 |
B 1.000 |
B 1.000 |
B 1.000 |
B 1.000 |
0.976 | B |
| Nitrates, long-term | C |
B 1.000 |
C 1.000 |
C 1.000 |
C 1.000 |
C 0.917 |
C 1.000 |
C 0.947 |
0.981 | C |
| Gp IIb/IIIa antagonists | C |
B 0.875 |
C 1.000 |
C 1.000 |
C 1.000 |
C 0.917 |
C 0.875 |
C 1.000 |
0.952 | C |
| Ivabradine | C |
B 0.750 |
C 1.000 |
C 1.000 |
C 1.000 |
C 1.000 |
C 1.000 |
C 1.000 |
0.964 | C |
| Lowest overall mean consensus coefficient (BPSD: depression = 0.907) | ||||||||||
| Substance/group | ||||||||||
| SSRIs (citalopram/escitalopram, sertraline, fluoxetine in the usual dosages) | C |
C 0.750 |
C 1.000 |
C 0.750 |
C 1.000 |
B 0.917 |
C 1.000 |
C 0.900 |
0.902 | C |
| Mirtazapine (15–45 mg/day) | C |
C 0.750 |
C 1.000 |
C 0.750 |
C 1.000 |
C 1.000 |
C 1.000 |
C 0.925 |
0.918 | C |
| SNRIs (venlafaxine, duloxetine) | C |
D 0.750 |
C 1.000 |
C 0.750 |
C 1.000 |
C 0.929 |
C 1.000 |
D 0.875 |
0.901 | C |
FORTA Fit fOR The Aged, BPSD Behavioral and Psychological Symptoms of Dementia, ACE angiotensin-converting enzyme, rTPA recombinant tissue-type plasminogen activator, GP glycoprotein, SSRIs selective serotonin reuptake inhibitors, SNRIs serotonin noradrenaline reuptake inhibitors
aOncological diseases are not depicted as the high number of abstentions may have biased the results